# A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations

> **NCT07646821** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Ropeginterferon
- Alfa-2b
- Azacitidine
- MDS/AML

## Interventions

- **DRUG:** ropeginterferon alfa- 2b
- **DRUG:** Azacitidine (AZA)

## Key facts

- **NCT ID:** NCT07646821
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-27
- **Primary completion:** 2028-12-11
- **Final completion:** 2030-12-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07646821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07646821, "A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07646821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*